Discover all OncoDNA videos explaining how OncoDNA supports cancer patients and healthcare specialists in the therapeutic decision-making process.
Scroll down to discover
OncoDNA has become a group of companies specializing in precision medicine for the treatment of cancer and genetic diseases. Discover who we are and what we do.
OncoDEEP is a comprehensive biomarker test designed to inform the selection of the most effective treatment options for patients with advanced, metastatic solid tumors.
With advances in precision medicine, there now exist therapies that target gene fusion in solid tumors. What are the methods available to detec those complex biomarkers in patients?
OncoDNA has developed OncoKDM, an online platform that allows the different cancer treatment facilities around the world to benefit from the expertise of OncoDNA by interpreting their sequencing data and other tests performed in their laboratory.
Immunotherapy is becoming the standard of cancer care. However, immunotherapy does not work for all patients. How to differentiate responders from non responders? OncoDNA helps oncologists predict a cancer patient's reponse to immunotherapy in one single test that combines the analysis of multiple biomarkers:
Jacqui Gath is a cancer survivor. Based on her past experience, she shares advice with patients living with a cancer and explains why it is so important for them to steer their own journey explaining why it’s good to work with their doctors, staying in control of their choices so that they tailor the treatment pathway that is right for them.
Patient Cecilia Guerra suffered from an unknown primary tumour for which no effective treatment could be found, until her oncologist, Dr. Omar Castillo, Chief Oncologist at the National Oncology Institute of Panama, recommended OncoDEEP, a biomarker test provided by OncoDNA.
Virgine was diagnosed with breast cancer. After 5 years of fight against her disease, biomarker testing brought her hope for a new treatment. She tells you her story along with her oncologist, Dr Wagner.
Added : 29 Nov 2019
Christine was diagnosed in 2017 with uterus cancer. The OncoStrat&Go molecular profiling report annotated that Christine would not react positively to Dacarbazine but only to Doxorubicin. Thus avoiding her some adverse drug reactions.
According to Prof. Dr. Marc Peeters, the answer is clear, both have to exchange data and knowledge to perform the right testing in terms of biomarkers to get the right treatment options for the patient.
In 2015 the patient (a female 50-year-old) was diagnosed with a NSCLC stage IV. Based on the results generated with OncoDEEP, the oncologist decided to treat the patient with crizotinib.
63-year-old man affected by an unknown Head&Neck primary site poorly differentiated into a squamous cell carcinoma. OncoDNA observed a high expression of PD-L1 which is associated with a good prognosis for such therapy. The patient is treated with nivolumab and shows a good response with 6 months of OS for the moment.
Le Dr Jean-Loup MOUYSSET est Oncologue et fondateur de l’Association Ressource et du Centre ressource situé à Aix en Provence. Il s'agit d'un lieu d’accueil pour les personnes touchées par le cancer. Le Dr MOUYSSET utilise nos tests OncoDEEP pour l'aider dans ses choix de traitements.
Clinomics is a liquid biopsy based cancer diagnostic company which has included OncoKDM interpretation platform to study cancer biomarkers. Discover why they have chosen to work with OncoKDM.
Reportage about OncoDNA and interviews with Jean-Pol Detiffe, Founder, and Fiona Demol, Head of Marketing.
Jean-Pol Detiffe, OncoDNA's CEO, interviewed for "Ziggo Kanaal 42", a regional TV in the Netherlands
In the "Company of the year" competition 2015 organized by Ernst & Young, OncoDNA was designated as the most promising company of the year / Lors du concours "L'entreprise de l'année" 2015 organisé par Ernst & Young, OncoDNA fut désignée Entreprise la plus prometteuse.
La RTBF parle de l'Entreprise la plus prometteuse de l'année 2015 dans son JT du soir. Petit reportage dans les laboratoires de l'IPG et visite de nos bureaux.
OncoDNA lève un capital de 7,7 millions d'euros pour financer son ambitieux programme de croissance.